Ep. 3: Time Toxicity, CNS Risk, and Sequencing Strategy in EGFR-Mutant NSCLC
Key Points
-
Subcutaneous amivantamab, including once-monthly dosing, significantly reduces time toxicity and infusion-related burden.
-
Patients with baseline central nervous system (CNS) metastases derived substantial benefit from up-front combination therapy in MARIPOSA.
-
Toxicity profiles, patient preference, and sequencing strategy increasingly guide regimen selection in first-line EGFR-mutant non–small cell lung cancer (NSCLC).
Time Toxicity and Patient-Centered Care
The frontline management of classical EGFR-mutant metastatic NSCLC continues to evolve, as highlighted in a panel moderated by Eric Singhi, MD, of The University of Texas MD Anderson Cancer Center, with panelists Fawzi Abu Rous, MD, of Henry Ford Health; Sarah Goldberg, MD, MPH, of Yale School of Medicine; Julia Rotow, MD, of Dana-Farber Cancer Institute; and Susan C. Scott, MD, of Johns Hopkins Medicine. Dr. Singhi used two analogies to frame treatment strategy: “a marathon, not a sprint” and “chess, not checkers.”
A key theme was the underrecognized concept of “time toxicity.” With the approval of subcutaneous amivantamab, including once-monthly dosing, panelists emphasized the meaningful reduction in patient burden. Dr. Abu Rous called the formulation a game changer, noting not only fewer visits but dramatically shorter administration times. Dr. Goldberg highlighted the contrast—“5 hours versus 5 minutes”—while Dr. Scott pointed out that monthly dosing represents a 25% reduction in infusion visits, particularly impactful for patients traveling long distances.
Collectively, the panel stressed that reducing time in the cancer center is a tangible quality-of-life benefit that should factor into shared decision-making.
CNS Disease, Combination Strategy, and Toxicity Selection
CNS involvement remains a defining high-risk feature in EGFR-mutant NSCLC. Revisiting this unmet need, Dr. Rotow explained that MARIPOSA evaluated CNS outcomes. MARIPOSA incorporated serial brain MRIs for all patients, allowing assessment of intracranial progression-free survival (PFS).
Toxicity profiles differ meaningfully between regimens and often guide treatment selection. MARIPOSA requires proactive dermatologic management due to dual EGFR inhibition. As Dr. Goldberg summarized, while combination therapy is now the default for many clinicians, “they both have pros and cons.” Selection often hinges on anticipated tolerability and patient preference.
Dr. Scott emphasized the need for biologically driven selection rather than reliance solely on logistics and adverse effect profiles. “I hope that in the coming years, we’ll be able to select patients who do better with an IV amivantamab strategy, who do better with chemo strategy,” she said.